Need professional-grade analysis? Visit stockanalysis.com
$13.62B
236.54
1,060
N/A
Shenzhen Chipscreen Biosciences Co (688321) trades on SHG in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY30.90, down 2.31% from the previous close.
Over the past year, 688321 has traded between a low of CNY16.64 and a high of CNY42.97. The stock has gained 84.4% over this period. It is currently 28.1% below its 52-week high.
Shenzhen Chipscreen Biosciences Co has a market capitalization of $13.62B, with a price-to-earnings ratio of 236.54.
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor. The company was founded in 2001 and is headquartered in Shenzhen, China.
Side-by-side comparison against top Healthcare peers.